Could Ghrelin Expression Regulate Diastolic Cardiac Function in Type 2 Diabetic Obese Patients?

Diabetes/metabolism research and reviews 2025 Vol.41(4) p. e70049

Sardu C, D'Onofrio N, Trotta MC, Balestrieri ML, Nicoletti GF, D'Amico G, Fumagalli C, Contaldi C, Pacileo G, Scisciola L, Nicoletti M, Marfella LV, Sbriscia M, Sasso FC, Signoriello G, Paolisso G, Marfella R

Abstract

[AIMS] Adipose tissue expresses cytokines, sirtuin-1 (SIRT1), and microRNAs (miRs), regulating left ventricle (LV)-diastolic function (LV-DF). Ghrelin could modulate these pathways in patients with type 2 diabetes mellitus (T2DM) and obesity. We investigated ghrelin expression in T2DM obese patients after abdominal fat excision, and in those with LV-DF normalisation at 1 year of follow-up.

[MATERIALS AND METHODS] Two-hundred and two T2DM obese patients enroled for abdominoplastic surgery were divided into those with normal LV-DF (group 1: E/E' < 9, n 76) and those with altered LV-DF: group 2 (9 < E/E' < 14; n 96) and group 3 (E/E' > 14, n 28).

[RESULTS] Patients with LV-diastolic dysfunction had over-inflammation, lower SIRT1 and higher abdominal fat sodium-glucose-transporter-two (SGLT2) expression (p < 0.05). They did not differ for ghrelin expression (p > 0.05). They evidenced different tissue/serum expression of miR-21, miR-92 and miR-126 (p < 0.05). Group 2 versus group 1 over-expressed tissue inflammatory markers and SGLT2 (p < 0.05), with higher extent in group 3 versus group 1 (p < 0.01) and versus group 2 (p < 0.025). SIRT1 was downregulated in group 2 versus group 1 (p < 0.05), and versus group 3 (p < 0.01). At the follow-up end, patients with lower LV-diastolic dysfunction had lower inflammation and SGLT2, and higher serum ghrelin (p < 0.05). They increased miR-126, and reduced serum miR-21 and miR-92 expression. At the follow-up end, 50 patients experienced LV-DF normalisation, which was predicted by tissue miR-126 (HR 1.344, CI 95% 1.126-1.937), and ghrelin (HR 1.123, CI 95% 1.016-1.310).

[CONCLUSIONS] In T2DM obese patients, abdominal fat excision could reduce inflammation, up-regulating serum ghrelin and inducing miRs implied in LV-DF normalisation at 1 year of follow-up.

[CLINICAL RESEARCH TRIAL NUMBER] NCT05988346.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 ventricle scispacy 1
해부 abdominal fat scispacy 1
해부 tissue scispacy 1
해부 serum ghrelin scispacy 1
해부 serum scispacy 1
해부 Cardiac scispacy 1
해부 Adipose tissue scispacy 1
합병증 abdominal fat scispacy 1
약물 [CONCLUSIONS] In scispacy 1
약물 tissue/serum scispacy 1
질환 Diabetic C0241863
diabetic
scispacy 1
질환 type 2 diabetes mellitus C0011860
Diabetes Mellitus, Non-Insulin-Dependent
scispacy 1
질환 T2DM → type 2 diabetes mellitus C0011860
Diabetes Mellitus, Non-Insulin-Dependent
scispacy 1
질환 obesity C0028754
Obesity
scispacy 1
질환 LV-diastolic dysfunction C0520863
Diastolic dysfunction
scispacy 1
질환 inflammation C0021368
Inflammation
scispacy 1
기타 E/E scispacy 1
기타 SGLT2 scispacy 1
기타 miR-21 scispacy 1
기타 miR-92 scispacy 1
기타 miR-126 scispacy 1
기타 HR 1.123 scispacy 1
기타 miRs → microRNAs scispacy 1
기타 Ghrelin scispacy 1
기타 Type 2 scispacy 1
기타 Patients scispacy 1
기타 sirtuin-1 scispacy 1
기타 SIRT1 → sirtuin-1 scispacy 1

MeSH Terms

Female; Humans; Male; Middle Aged; Biomarkers; Diabetes Mellitus, Type 2; Diastole; Follow-Up Studies; Ghrelin; MicroRNAs; Obesity; Prognosis; Sirtuin 1; Ventricular Dysfunction, Left; Ventricular Function, Left